NASDAQ$MBRX
Moleculin Biotech Inc · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Moleculin reported financial results for the year ended December 31, 2019.
Moleculin Biotech, Inc. reported a net loss of $13.2 million for the year ended December 31, 2019. The company's cash and cash equivalents were $10.7 million as of December 31, 2019. They believe that their cash resources will be sufficient to meet operating requirements towards the end of the third quarter of 2020.
- Annamycin met its primary endpoint and demonstrated a clean safety profile with no evidence of cardio-toxicity in Phase 1 portion of US Phase 1/2 clinical trial in AML.
- Emory University received FDA approval for their IND status request for WP1066 in a pediatric brain tumor clinical trial.
- Positive data reported from Phase 1 ‘proof-of-concept’ clinical trial with WP1220 for the treatment of cutaneous T-cell lymphoma (CTCL), which demonstrated a median reduction of 56% in skin cancer lesions.
- Preclinical testing of WP1122 began as a new approach to Pancreatic cancer, by attacking cancer through inhibiting tumor metabolism.
Headline financials
Revenue & EPS history
Moleculin · Revenue · Quarterly
$0
Forward guidance
Moleculin anticipates several milestones in 2020, including the first patient treated in the Phase 1 clinical trial with WP1066, IND submission for Annamycin, pre-IND Meeting with FDA/EMA concerning a Phase 2 clinical trial with WP1220, FDA End of Phase 1 meeting for Annamycin in AML, achieving an MTD or a dose level at or above 300 mg/m2 in EU AML Phase 1/2 trial for Annamycin, and benefiting from non-dilutive financial funding for additional clinical trials
Tailwinds
- First patient treated in the Phase 1 clinical trial with WP1066 for the treatment of pediatric brain tumors at Emory University
- IND submission for Annamycin for the treatment of tumor metastases to the lung
- Pre-IND Meeting with FDA/EMA concerning a Phase 2 clinical trial with WP1220 for the treatment of CTCL
- File IND/CTA for a Phase 2 clinical trial with WP1220 for the treatment of CTCL
- FDA End of Phase 1 meeting for Annamycin in AML
Headwinds
- Achieving an MTD or a dose level at or above 300 mg/m2 in EU AML Phase 1/2 trial for Annamycin
- Benefit from non-dilutive financial funding for additional clinical trials
- The ability of Moleculin to successfully recruit sufficient patients to complete its current clinical trials
- The ability of Moleculin to be permitted by the FDA to accelerate its approval pathway for a pivotal Phase 2 trial by relying on its European trial to establish a recommended Phase 2 dose
- The ability of Moleculin to file an IND for the treatment of cancer metastases to the lung in 2020
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2019
-1.2%
Avg return
Earnings day
-0.8%
Avg return
5 days after
-5.3%
Avg return
30 days after
32%
13 / 41 earnings
Positive
+28.1%
Q4 2019
Best reaction
-20.8%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.8% | +9.8% | — | |
| Q4 2025 | +0.0% | +20.9% | +17.5% | |
| Q3 2025 | -4.4% | -3.5% | -56.1% | |
| Q2 2025 | -4.0% | -11.7% | -46.1% | |
| Q1 2025 | -8.2% | -1.3% | -35.3% | |
| Q4 2024 | -2.8% | -3.7% | -12.8% | |
| Q3 2024 | +3.5% | +6.3% | +3.9% | |
| Q2 2024 | -5.1% | +2.1% | +3.4% | |
| Q1 2024 | +1.9% | +6.7% | -9.2% | |
| Q4 2023 | -20.8% | -16.4% | -29.9% | |
| Q3 2023 | +1.9% | +9.3% | -2.4% | |
| Q2 2023 | -1.3% | -7.5% | -32.7% | |
| Q1 2023 | -14.4% | -21.7% | -23.1% | |
| Q4 2022 | -1.9% | -7.8% | -24.0% | |
| Q3 2022 | +5.1% | +6.1% | +48.6% | |
| Q2 2022 | +9.3% | +3.7% | -12.3% | |
| Q1 2022 | +1.6% | +9.0% | +23.0% | |
| Q4 2021 | -4.4% | -1.7% | +1.1% | |
| Q3 2021 | +0.0% | -6.5% | -5.7% | |
| Q2 2021 | -3.3% | -11.1% | -0.3% | |
| Q1 2021 | -3.8% | -2.1% | -99.7% | |
| Q4 2020 | -1.5% | -6.6% | -11.6% | |
| Q3 2020 | +2.9% | +8.5% | +14.1% | |
| Q2 2020 | -7.4% | -5.6% | -29.0% | |
| Q1 2020 | +0.0% | +0.0% | +11.2% | |
| Q4 2019 | +28.1% | +27.9% | +155.9% | |
| Q3 2019 | +0.9% | -0.9% | -4.7% | |
| Q2 2019 | +6.5% | +10.2% | +13.0% | |
| Q1 2019 | -0.8% | -5.7% | -4.9% | |
| Q4 2018 | +3.8% | -1.5% | -0.8% | |
| Q3 2018 | -3.1% | +6.1% | -3.8% | |
| Q2 2018 | +0.0% | -1.2% | +0.0% | |
| Q1 2018 | -0.6% | -0.6% | +12.1% | |
| Q4 2017 | -3.2% | -1.1% | -0.5% | |
| Q3 2017 | -0.4% | +3.7% | +5.6% | |
| Q2 2017 | -7.7% | -11.8% | -3.7% | |
| Q1 2017 | -4.7% | -4.9% | +0.0% | |
| Q4 2016 | -12.8% | -28.2% | -27.4% | |
| Q3 2016 | -2.4% | +1.7% | -50.5% | |
| Q2 2016 | -1.6% | -6.7% | -1.0% | |
| Q1 2016 | +2.3% | +5.4% | +5.2% | |
| Q3 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro